1. Home
  2. SSL vs PTCT Comparison

SSL vs PTCT Comparison

Compare SSL & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sasol Ltd.

SSL

Sasol Ltd.

HOLD

Current Price

$5.99

Market Cap

3.8B

Sector

Energy

ML Signal

HOLD

Logo PTC Therapeutics Inc.

PTCT

PTC Therapeutics Inc.

HOLD

Current Price

$77.48

Market Cap

5.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSL
PTCT
Founded
1950
1998
Country
South Africa
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
5.3B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
SSL
PTCT
Price
$5.99
$77.48
Analyst Decision
Buy
Analyst Count
0
17
Target Price
N/A
$73.76
AVG Volume (30 Days)
945.5K
2.3M
Earning Date
01-01-0001
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.59
8.94
Revenue
$14,028,282,389.00
$1,779,150,000.00
Revenue This Year
$1.17
$128.32
Revenue Next Year
$6.50
N/A
P/E Ratio
$10.13
$8.64
Revenue Growth
N/A
97.54
52 Week Low
$2.78
$35.95
52 Week High
$7.39
$87.50

Technical Indicators

Market Signals
Indicator
SSL
PTCT
Relative Strength Index (RSI) 38.62 54.29
Support Level $6.27 $73.03
Resistance Level $6.46 $79.03
Average True Range (ATR) 0.15 3.38
MACD -0.11 -0.70
Stochastic Oscillator 2.11 29.37

Price Performance

Historical Comparison
SSL
PTCT

About SSL Sasol Ltd.

Sasol Ltd operates as a vertically integrated chemicals and energy company through its two main businesses: the Southern Africa Energy & Chemicals business and the International Chemical business. It generates maximum revenue from the Southern Africa Energy & Chemicals business, which operates integrated value chains with feedstock sourced from the Mining and Gas operating segments. Geographically, the company generates the majority of its revenue from South Africa.

About PTCT PTC Therapeutics Inc.

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.

Share on Social Networks: